Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 7/20 | 0.36 |
| ▸ | DUT | P33316 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.33 |
| ▸ | TK2 | O00142 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082091 | 0.73 | KIF11 (0.46) | KIF11TK1DUTCYP2C9ALOX15 | |
| SCHEMBL6170590 | 0.70 | TSHR (0.48) | CYP2C9TSHRCYP2C19MEN1KMT2A | |
| SCHEMBL22091847 | 0.70 | KIF11 (0.43) | KIF11TK1DUTCYP2C9ALOX15 | |
| SCHEMBL29805216 | 0.70 | KIF11 (0.43) | KIF11TK1CYP2C9ALOX15TSHR | |
| SCHEMBL7524693 | 0.70 | KIF11 (0.50) | KIF11TK1DUTCYP2C9ALOX15 | |
| SCHEMBL13479250 | 0.68 | TDP1 (0.49) | CYP2C9TSHRCYP2C19KMT2A | |
| SCHEMBL20569075 | 0.67 | KIF11 (0.44) | KIF11TK1DUTCYP2C9ALOX15 | |
| SCHEMBL187156 | 0.67 | SMYD2 (0.37) | — | |
| SCHEMBL9039609 | 0.67 | KIF11 (0.57) | KIF11TK1DUTCYP2C9ALOX15 | |
| SCHEMBL9865376 | 0.66 | KIF11 (0.56) | KIF11TK1DUTCYP2C9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| EP-2146989-B1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA AS (DK) | 2012-01-04 | — | — | EP | disclosed |
| EP-2146989-B1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA AS (DK) | 2012-01-04 | — | — | EP | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| EP-2146989-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | Leo Pharma A/S (DK) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125111-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125111-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | PDE5A, PDE3A, PDE3B | KIF11 4167/4885TK1 124/4885DUT 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.